Trial
NCT03176277
A Study of ONO-7475 in Patients With Acute Leukemias
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Ono Pharmaceutical Co., Ltd.
Collaborators
—
Condition
Acute Leukemia
Intervention
ONO-7475 3mg once daily
Why stopped
Protocol defined futility criteria
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-15